ArticleCerebral circulation - cognition and behavior2026
Defining patient-reported outcomes and priorities for clinical trials in CADASIL through an international survey.
Article in Cerebral circulation - cognition and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A major challenge faced by clinical trials for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the heterogeneity of symptoms and variable progression pace, while treatments should attenuate symptoms that bother patients most. To this end, we set to describe the symptomatic landscape for CADASIL with the ultimate goal of developing Patient Reported Outcomes (PRO) for clinical trials. Methods: A survey was compiled through iterative consensus meetings between patients, family members, CADASIL clinicians, and patient advocacy group members (cureCADASIL). The final questionnaire included demographic information, subjective symptom severity ratings, medication use and lifestyle factors. Data were collected over a period of 16 months from 11/2023 to 3/2025 and analyzed through descriptive and quantitative methods. Results: We collected 226 responses from 25 countries. The average age of responders was 52 (SD 12) years, and 158 (69.9 %) identified as women. Out of all symptoms, fatigue was reported as the most frequent (86.3 %), and most bothersome (14.2 %). Symptom severity differed across age groups only for headaches, with younger participants reporting higher scores (Kruskal-Wallis χ² = 8.64, p = 0.03). All symptoms were intercorrelated, with strongest clustering among congruent categories such as slowed thinking, cognitive fog, and memory complaints (Spearman's ρ ≥ 0.70, adjusted p < 0.001). Medication use was widespread: 156 participants (69 %) reported prescription medications, 116 (51.3 %) over-the-counter drugs, and 128 (56.6 %) supplements. Conclusions: By identifying symptom domains most salient to patients, our study provides a foundation for the development of PRO tools in CADASIL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.